Resources for Physicians

The Moderate Alcohol and Cardiovascular Health (MACH15) Trial is a large-scale,
international research trial funded by the National Institutes of Health to answer the following questions:


The Primary Specific Aim of this randomized trial is:

1 To determine the effects of moderate alcohol intake daily compared with abstention on risk of major cardiovascular events or death (myocardial infarction, ischemic stroke, hospitalized angina, need for revascularization, or death) over an average of 6 years of follow-up among 7,800 adults aged ≥50 years with estimated 10-year CVD risk ≥15% or prevalent CVD >6 months prior to enrollment.


Secondary Aims are to determine the effects of moderate alcohol intake daily on:

2 Incident diabetes among those participants free of diabetes at enrollment


3 Incident CVD (myocardial infarction, ischemic stroke, CVD mortality, hospitalized angina, or need for revascularization)



Tertiary Aims are to determine the effects of moderate alcohol intake daily on:

4 Restricted CVD (myocardial infarction, ischemic stroke, CVD mortality)


5 Progression to impaired fasting glucose among normoglycemic individuals at enrollment



The trial will enroll 7,800 participants at over 20 clinics worldwide. Enrollment is set to begin in Summer 2017.